81.2600.63% ( +0.510 )
Delay Trading: Nov 9, 15:07:48 (EDT)Current ValuationThe current P/E ratio is -409.65, below the reasonable range, cheaper than 99.77% of the time in the past 5 years, and the industry ranks 56/58, the industry Median -1.33.
-409.65xP/E
$80.75Stock price
$-0.20Earnings per share
-409.65xP/E
Stock price$80.75Earnings per share$-0.20
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 36.07x
- Typical range
- 16.04x–59.34x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0114228342456
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
LZAGYUSLonza | -409.65x | -- | $56.40B |
TEMUSTempus AI | -72.08x | 25.30% | $13.64B |
RGENUSRepligen | -939.52x | 134.76% | $11.09B |
BRKRUSBruker | -55.97x | 520.00% | $9.36B |
TXGUS10X Genomics | -116.24x | 89.24% | $7.80B |
ADPTUSAdaptive Biotechnologies | -64.22x | 0.85% | $4.53B |
ABCLUSAbcellera Biologics | -23.38x | 36.29% | $3.85B |
FTREUSFortrea | -30.85x | 95.76% | $2.12B |
MRVIUSMaravai LifeSciences | -29.74x | 68.89% | $1.95B |
ALMRUSAlamar Biosciences | -35.43x | 79.42% | $1.95B |
AZTAUSAzenta | -13.96x | 176.92% | $1.72B |
PSNLUSPersonalis | -14.34x | 18.96% | $1.71B |
CYRXUSCryoport | -19.64x | 161.51% | $968.38M |
CTKBUSCytek Biosciences | -9.39x | 33.98% | $762.47M |
DNAUSGinkgo Bioworks | -3.03x | 35.20% | $760.27M |
OABIUSOmniAb | -16.88x | 39.35% | $733.68M |
PACBUSPacific Biosc California | -5.38x | 76.92% | $705.65M |
EVOUSEvotec SE | -2.89x | 338.09% | $600.30M |
TKNOUSAlpha Teknova | -30.76x | 9.82% | $491.27M |
QSIUSQuantum-Si | -3.42x | 12.42% | $291.12M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
